<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02189122</url>
  </required_header>
  <id_info>
    <org_study_id>140707</org_study_id>
    <nct_id>NCT02189122</nct_id>
  </id_info>
  <brief_title>Comparative Effects of Aspirin and NHP-544C</brief_title>
  <official_title>Comparative Effects of Rapid-Release Aspirin and NHP-544C on Basal and Bradykinin Stimulated Prostacyclin Production</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will compare the effects of rapid release aspirin and NHP-544C on the
      prostacyclin response to intravenous bradykinin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Thromboxane Concentrations at Placebo ASA or Placebo NHP-544C Dose</measure>
    <time_frame>24 hour collection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Thromboxane Concentrations at 81mg ASA or NHP-544C Dose</measure>
    <time_frame>24 hour collection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Thromboxane Concentrations at 162.5 mg ASA or NHP-544C Dose</measure>
    <time_frame>24 hour collection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Prostacyclin Concentrations at Placebo ASA or Placebo NHP-544C Dose</measure>
    <time_frame>24 hour collection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Prostacyclin Concentrations at 81 mg ASA or NHP-544C Dose</measure>
    <time_frame>24 hour collection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Prostacyclin Concentrations at 162.5 mg ASA or NHP-544C Dose</measure>
    <time_frame>24 hour collection</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1:Aspirin/placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2:NHP-544C/placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bradykinin</intervention_name>
    <description>Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.</description>
    <arm_group_label>Group 1:Aspirin/placebo</arm_group_label>
    <arm_group_label>Group 2:NHP-544C/placebo</arm_group_label>
    <other_name>BK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81 mg</intervention_name>
    <description>Subjects will take Aspirin 81 mg per day for five days.</description>
    <arm_group_label>Group 1:Aspirin/placebo</arm_group_label>
    <other_name>ASA 81 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 162 mg</intervention_name>
    <description>Subjects will take aspirin 162 mg per day for 5 days.</description>
    <arm_group_label>Group 1:Aspirin/placebo</arm_group_label>
    <other_name>ASA 162 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NHP544-C 81 mg</intervention_name>
    <description>Subjects will take NHP544C 81 mg per day for five days.</description>
    <arm_group_label>Group 2:NHP-544C/placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NHP544C 162 mg</intervention_name>
    <description>Subjects will take NHP544C 162 mg once a day for five days.</description>
    <arm_group_label>Group 2:NHP-544C/placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will take matching placebo for five days.</description>
    <arm_group_label>Group 1:Aspirin/placebo</arm_group_label>
    <arm_group_label>Group 2:NHP-544C/placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages of 18 and 55 years, inclusive

          2. No significant medical issues without significant abnormal findings at the baseline
             physical examination

          3. Body mass index (BMI) between 18.0 and 30.0kg/m2 (weight (kg)/[height(m)]2)

          4. For women - negative pregnancy test on Period 1, Day -1, or surgically sterilized, or
             is at least two years post-menopausal prior to randomization. Females of childbearing
             potential must be practicing an acceptable method of birth control to be eligible.
             Acceptable forms of birth control include: condom plus spermicide or condom plus other
             form of birth control including hormonal method (IUD, patch, ring, implant, or
             injectable), sterilization of partner, or non-hormonal IUD. The use of oral
             contraceptives is allowed during the study, but the subject must be on a stable dose
             for 30 days prior to the trial and throughout all four dosing periods

          5. Ability to understand the requirements of the study and a willingness to comply with
             all study procedures

        Exclusion Criteria:

          1. Clinically significant and relevant medical history (including failure of a major
             organ system) or current medical illness, and is deemed by the Principal Investigator
             to be unsuitable to participate in the study

          2. Participation in an investigational drug study within the 30 days prior to CRC
             admission

          3. Use of aspirin or other NSAID within 14 days of Day 1 of the study. All other
             medications, prescription (with the exception of contraceptives), over-the-counter
             (OTC), herbal, and vitamin supplements must be discontinued 7 days prior to Day 1. If
             subjects are taking prescription medication, or OTC medication at the direction of a
             health care provider, that provider must confirm that it is acceptable for them to
             stop dosing for the duration of the study

          4. History of metabolic, renal, hepatic, hemorrhagic stroke, gastrointestinal bleed,
             cardiovascular disease, central nervous system disorder, or peptic ulcer disease or
             other chronic bleeding disorder

          5. History of gastrointestinal disorder that could result in incomplete absorption of the
             study drug

          6. Malignancy, or neurologic or psychiatric disorder

          7. Abnormal laboratory value(s) determined to be clinically significant (in the opinion
             of the Investigator)

          8. History of illicit drug abuse in the past year or current evidence of such abuse in
             the opinion of the investigator

          9. Pregnancy or lactation

         10. Acute illness within 1 week of CRC admission

         11. Significant loss of blood or blood or plasma donation within 30 days of drug
             administration

         12. Hypersensitivity or allergy to NSAIDs, aspirin, ethylcellulose, polyvidone, castor
             oil, magnesium stearate, tartaric acid, colloidal anhydrous silica, talc, gelatin,
             titanium dioxide, erythrosine, or indigotin

         13. History of aspirin resistance

         14. History of alcohol abuse within past year. Current alcohol use should not exceed 14
             standard alcoholic drinks per week. A drink is defined as 1.5 ounces (oz.) liquor, 12
             oz. beer, or 6 oz. wine

         15. Alcohol consumption within 3 days of Day 1

         16. Difficulty swallowing oral medications

         17. Consumption of coffee or caffeine-containing beverages exceeding the equivalent of
             five 8-oz cups of coffee per day on average
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gamboa JL, Devin JK, Ramirez CE, Yu C, Nian H, Lee RH, Brown NJ. Comparative effects of immediate-release and extended-release aspirin on basal and bradykinin-stimulated excretion of thromboxane and prostacyclin metabolites. Pharmacol Res Perspect. 2016 Feb 23;4(2):e00221. doi: 10.1002/prp2.221. eCollection 2016 Apr.</citation>
    <PMID>27069632</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2014</study_first_submitted>
  <study_first_submitted_qc>July 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2014</study_first_posted>
  <results_first_submitted>March 18, 2016</results_first_submitted>
  <results_first_submitted_qc>April 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2016</results_first_posted>
  <last_update_submitted>June 3, 2016</last_update_submitted>
  <last_update_submitted_qc>June 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown</investigator_full_name>
    <investigator_title>M.D.; Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Kininogens</mesh_term>
    <mesh_term>Bradykinin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Twenty-five enrolled participants were excluded prior to randomization to study group because they did not meet inclusion or exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1:Aspirin/Placebo</title>
          <description>Group 1 will be randomized to receive rapid release aspirin (ASA, 81 mg), ASA 162.5 mg, or identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of study.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Aspirin 81 mg: Subjects will take Aspirin 81 mg per day for five days.
Aspirin 162 mg: Subjects will take aspirin 162 mg per day for 5 days.
Placebo: Subjects will take matching placebo for five days.
Three subjects participated in each possible sequence with the following exceptions: Four subjects participated in the sequence Aspirin 81 mg, Aspirin 162.5 mg, placebo; two subjects participated in the sequence placebo, Aspirin 162.5 mg, Aspirin 81 mg.</description>
        </group>
        <group group_id="P2">
          <title>Group 2:NHP-544C/Placebo</title>
          <description>Group 2 will be randomized to receive NHP-544C 81 mg, NPH-544C 162.5 mg or placebo. Bradykinin will be given intravenously in graded doses on the fifth day of study drug.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
NHP544-C 81 mg: Subjects will take NHP544C 81 mg per day for five days.
NHP544C 162 mg: Subjects will take NHP544C 162 mg once a day for five days.
Placebo: Subjects will take matching placebo for five days.
Three subjects participated in each possible sequence with the following exceptions: Four subjects participated in the sequence NHP544C 81 mg, NHP544C 162 mg, placebo; two subjects participated in the sequence NHP544C 162 mg, placebo, NHP544C 81 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1:Aspirin/Placebo</title>
          <description>Group 1 will be randomized to receive rapid release aspirin (ASA, 81 mg), ASA 162.5 mg, or identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of study.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Aspirin 81 mg: Subjects will take Aspirin 81 mg per day for five days.
Aspirin 162 mg: Subjects will take aspirin 162 mg per day for 5 days.
Placebo: Subjects will take matching placebo for five days.</description>
        </group>
        <group group_id="B2">
          <title>Group 2:NHP-544C/Placebo</title>
          <description>Group 2 will be randomized to receive NHP-544C 81 mg, NPH-544C 162.5 mg or placebo. Bradykinin will be given intravenously in graded doses on the fifth day of study drug.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
NHP544-C 81 mg: Subjects will take NHP544C 81 mg per day for five days.
NHP544C 162 mg: Subjects will take NHP544C 162 mg once a day for five days.
Placebo: Subjects will take matching placebo for five days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" lower_limit="24.2" upper_limit="33.6"/>
                    <measurement group_id="B2" value="26.5" lower_limit="24.1" upper_limit="28.4"/>
                    <measurement group_id="B3" value="27.1" lower_limit="24.1" upper_limit="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>11-dehydrothromboxane B2</title>
          <units>ng/mg creatinine</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.180" lower_limit="0.158" upper_limit=".240"/>
                    <measurement group_id="B2" value=".214" lower_limit=".191" upper_limit=".296"/>
                    <measurement group_id="B3" value=".206" lower_limit=".172" upper_limit=".272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2,3-dinor-6-keto-PGF1alpha</title>
          <units>ng/mg creatinine</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".1" lower_limit=".089" upper_limit=".139"/>
                    <measurement group_id="B2" value=".139" lower_limit=".117" upper_limit=".252"/>
                    <measurement group_id="B3" value=".121" lower_limit=".095" upper_limit=".158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urine Thromboxane Concentrations at Placebo ASA or Placebo NHP-544C Dose</title>
        <time_frame>24 hour collection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1:Aspirin/Placebo</title>
            <description>Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Aspirin 81 mg: Subjects will take Aspirin 81 mg per day for five days.
Aspirin 162 mg: Subjects will take aspirin 162 mg per day for 5 days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:NHP-544C/Placebo</title>
            <description>Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
NHP544-C 81 mg: Subjects will take NHP544C 81 mg per day for five days.
NHP544C 162 mg: Subjects will take NHP544C 162 mg once a day for five days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Thromboxane Concentrations at Placebo ASA or Placebo NHP-544C Dose</title>
          <units>ng/mg creatinine</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.181" lower_limit="0.143" upper_limit="0.216"/>
                    <measurement group_id="O2" value="0.255" lower_limit="0.219" upper_limit="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Thromboxane Concentrations at 81mg ASA or NHP-544C Dose</title>
        <time_frame>24 hour collection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1:Aspirin/Placebo</title>
            <description>Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Aspirin 81 mg: Subjects will take Aspirin 81 mg per day for five days.
Aspirin 162 mg: Subjects will take aspirin 162 mg per day for 5 days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:NHP-544C/Placebo</title>
            <description>Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
NHP544-C 81 mg: Subjects will take NHP544C 81 mg per day for five days.
NHP544C 162 mg: Subjects will take NHP544C 162 mg once a day for five days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Thromboxane Concentrations at 81mg ASA or NHP-544C Dose</title>
          <units>ng/mg creatinine</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0685" lower_limit="0.0585" upper_limit="0.0717"/>
                    <measurement group_id="O2" value="0.115" lower_limit="0.095" upper_limit="0.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Thromboxane Concentrations at 162.5 mg ASA or NHP-544C Dose</title>
        <time_frame>24 hour collection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1:Aspirin/Placebo</title>
            <description>Group 1 will be randomized to receive rapid release aspirin (ASA, 81 mg), ASA 162.5 mg, or identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of study.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Aspirin 81 mg: Subjects will take Aspirin 81 mg per day for five days.
Aspirin 162 mg: Subjects will take aspirin 162 mg per day for 5 days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:NHP-544C/Placebo</title>
            <description>Group 2 will be randomized to receive NHP-544C 81 mg, NPH-544C 162.5 mg or placebo. Bradykinin will be given intravenously in graded doses on the fifth day of study drug.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
NHP544-C 81 mg: Subjects will take NHP544C 81 mg per day for five days.
NHP544C 162 mg: Subjects will take NHP544C 162 mg once a day for five days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Thromboxane Concentrations at 162.5 mg ASA or NHP-544C Dose</title>
          <units>ng/mg creatinine</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.054" lower_limit="0.043" upper_limit="0.077"/>
                    <measurement group_id="O2" value="0.071" lower_limit="0.056" upper_limit="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Prostacyclin Concentrations at Placebo ASA or Placebo NHP-544C Dose</title>
        <time_frame>24 hour collection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1:Aspirin/Placebo</title>
            <description>Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Aspirin 81 mg: Subjects will take Aspirin 81 mg per day for five days.
Aspirin 162 mg: Subjects will take aspirin 162 mg per day for 5 days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:NHP-544C/Placebo</title>
            <description>Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
NHP544-C 81 mg: Subjects will take NHP544C 81 mg per day for five days.
NHP544C 162 mg: Subjects will take NHP544C 162 mg once a day for five days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Prostacyclin Concentrations at Placebo ASA or Placebo NHP-544C Dose</title>
          <units>ng/mg creatinine</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.102" lower_limit="0.083" upper_limit="0.116"/>
                    <measurement group_id="O2" value="0.144" lower_limit="0.128" upper_limit="0.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Prostacyclin Concentrations at 81 mg ASA or NHP-544C Dose</title>
        <time_frame>24 hour collection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1:Aspirin/Placebo</title>
            <description>Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Aspirin 81 mg: Subjects will take Aspirin 81 mg per day for five days.
Aspirin 162 mg: Subjects will take aspirin 162 mg per day for 5 days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:NHP-544C/Placebo</title>
            <description>Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
NHP544-C 81 mg: Subjects will take NHP544C 81 mg per day for five days.
NHP544C 162 mg: Subjects will take NHP544C 162 mg once a day for five days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Prostacyclin Concentrations at 81 mg ASA or NHP-544C Dose</title>
          <units>ng/mg creatinine</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.069" lower_limit="0.049" upper_limit="0.116"/>
                    <measurement group_id="O2" value="0.128" lower_limit="0.105" upper_limit="0.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Prostacyclin Concentrations at 162.5 mg ASA or NHP-544C Dose</title>
        <time_frame>24 hour collection</time_frame>
        <population>Data are given for 162.5 mg study day</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1:Aspirin/Placebo</title>
            <description>Group 1 will be randomized to receive rapid release aspirin (ASA, 81 mg), ASA 162.5 mg, or identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of study.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Aspirin 81 mg: Subjects will take Aspirin 81 mg per day for five days.
Aspirin 162 mg: Subjects will take aspirin 162 mg per day for 5 days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:NHP-544C/Placebo</title>
            <description>Group 2 will be randomized to receive NHP-544C 81 mg, NPH-544C 162.5 mg or placebo. Bradykinin will be given intravenously in graded doses on the fifth day of study drug.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
NHP544-C 81 mg: Subjects will take NHP544C 81 mg per day for five days.
NHP544C 162 mg: Subjects will take NHP544C 162 mg once a day for five days.
Placebo: Subjects will take matching placebo for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Prostacyclin Concentrations at 162.5 mg ASA or NHP-544C Dose</title>
          <population>Data are given for 162.5 mg study day</population>
          <units>ng/mg creatinine</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067" lower_limit="0.045" upper_limit="0.104"/>
                    <measurement group_id="O2" value="0.108" lower_limit="0.084" upper_limit="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1:Aspirin/Placebo</title>
          <description>Group 1 will be randomized to receive rapid release aspirin (ASA, 81 mg), ASA 162.5 mg, or identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of study.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Aspirin 81 mg: Subjects will take Aspirin 81 mg per day for five days.
Aspirin 162 mg: Subjects will take aspirin 162 mg per day for 5 days.
Placebo: Subjects will take matching placebo for five days.</description>
        </group>
        <group group_id="E2">
          <title>Group 2:NHP-544C/Placebo</title>
          <description>Group 2 will be randomized to receive NHP-544C 81 mg, NPH-544C 162.5 mg or placebo. Bradykinin will be given intravenously in graded doses on the fifth day of study drug.
Bradykinin: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
NHP544-C 81 mg: Subjects will take NHP544C 81 mg per day for five days.
NHP544C 162 mg: Subjects will take NHP544C 162 mg once a day for five days.
Placebo: Subjects will take matching placebo for five days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ST T wave changes following bradykinin infusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>low albumin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus or nasal congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy J. Brown, M.D.</name_or_title>
      <organization>VANDERBILT UNIVERSITY MEDICAL CENTER</organization>
      <phone>6153438701</phone>
      <email>nancy.j.brown@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

